Miura K, Torikai T, Yoshinaga K, Sato T
3rd Department of Internal Medicine, Gifu University, Japan.
Nihon Naibunpi Gakkai Zasshi. 1991 Mar 20;67(3):175-202. doi: 10.1507/endocrine1927.67.3_175.
We followed up 21 Cushing's disease patients (16 females and 5 males) aged 15 to 46 years, treated with reserpine (R) plus pituitary irradiation (PI). Mean duration of R administration and mean dose of PI were 24.5 +/- 10.8 (mean +/- SD) months and 54.0 +/- 9.8 Gy, respectively. Of them, four patients did not respond, one who received 66 Gy had brain necrosis and panhypopituitarism, and the other 16 patients (78%, 16/21) achieved initial remission. Of these 16 patients, there were 10 (aged 15 to 46 years) who were irradiated with 50 Gy or less (mean, 45.5 +/- 6.9 Gy), and 7 of them had initial response. As previously demonstrated effectiveness of the present regimen (R plus PI) could be evaluated by subjecting the patients to R-test, higher rate of remission was obtained among R-test responders (J. Clin. Endocrinol. Metab. 41:511, 1975). Eleven of our R-test responders in the present study showed an early onset of remission (6.9 +/- 5.7 months) as compared with 5 R-test non-responders (17.0 +/- 9.1, p less than 0.05). In addition, the response time positively correlated with the ratio of the difference between basal plasma cortisol (11-OHCS) levels before and after midnight administration of 8 mg dexamethasone (delta D8) divided by the difference between 24-h urinary excretion of 17-OHCS for 3 successive days before, during metyrapone (3.0 g/day, 6 divided dose, 2 days) administration and one day after (delta M). The sixteen patients were followed up until 1990 for a mean of 12.4 years (2.2 to 25.2 years). Among them, one died of unrelated illness with this regimen 4 years after achieving remission, 4 relapsed between 5 to 7 years follow-up, and the remaining 11 (52%, 11/21) had long-term remission for a mean of 15.7 +/- 9.0 years (2.2 to 25.2 years). Of them, there were 5 patients who were treated with PI with 50 Gy or less, and had long-term remission (5.8 to 24.4 with a mean of 17.6 +/- 7.6 years). During the long-term follow-up period of these 11 patients, endocrine assessment was carried out while off therapy. Basal urinary excretion of cortisol or 17-OHCS were were normal in all of the 11 patients, and 8 of 9 showed normal diurnal rhythm of plasma cortisol. Nine of 10 patients tested showed normal suppressibility by overnight 1 mg dexamethasone test and 6 of 9 showed normal response to CRH.(ABSTRACT TRUNCATED AT 400 WORDS)
我们对21例年龄在15至46岁的库欣病患者(16例女性和5例男性)进行了随访,这些患者接受了利血平(R)加垂体照射(PI)治疗。利血平给药的平均持续时间和垂体照射的平均剂量分别为24.5±10.8(平均±标准差)个月和54.0±9.8 Gy。其中,4例患者无反应,1例接受66 Gy照射的患者发生脑坏死和全垂体功能减退,其他16例患者(78%,16/21)实现了初始缓解。在这16例患者中,有10例(年龄15至46岁)接受了50 Gy或更低剂量的照射(平均,45.5±6.9 Gy),其中7例有初始反应。如先前证明的,本方案(R加PI)的有效性可通过对患者进行R试验来评估,R试验反应者的缓解率更高(《临床内分泌与代谢杂志》41:511,1975)。在本研究中,我们的11例R试验反应者与5例R试验无反应者相比,缓解出现较早(6.9±5.7个月对17.0±9.1个月,p<0.05)。此外,反应时间与午夜给予8 mg地塞米松前后基础血浆皮质醇(11-羟皮质类固醇)水平之差除以甲吡酮(3.0 g/天,分6次给药,共2天)给药期间及给药后1天连续3天的24小时尿17-羟皮质类固醇排泄量之差的比值呈正相关(δM)。这16例患者随访至1990年,平均随访12.4年(2.2至25.2年)。其中,1例在缓解4年后因与本方案无关的疾病死亡,4例在随访5至7年时复发,其余11例(52%,11/21)实现长期缓解,平均缓解时间为15.7±9.0年(2.2至25.2年)。其中,有5例接受50 Gy或更低剂量垂体照射治疗的患者实现了长期缓解(5.8至24.4年,平均17.6±7.6年)。在这11例患者的长期随访期间,在停药时进行了内分泌评估。11例患者的基础尿皮质醇或17-羟皮质类固醇排泄均正常,9例中有8例血浆皮质醇昼夜节律正常。10例接受测试的患者中有9例过夜1 mg地塞米松试验抑制正常,9例中有6例对促肾上腺皮质激素释放激素反应正常。(摘要截取自400字)